You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advancement to IND of novel BLI for pairing with cefixime
SBC: VENATORX PHARMACEUTICALS INC Topic: NIAIDProject Summary Abstractlactam antibiotics are the most widely used antibiotic class in the U Saccounting for more thanof antibacterial prescriptionsAmong other rolesthey are critical therapeutics for difficult to treat infections due to gram negative pathogens such as EcoliKlebsiella pneumoniaeand Enterobacter sppHoweverthe utility of this class of antibiotics is being rapidly compromised by the ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Kinetic Phenotype Discovery Informatics for Neurological Diseases
SBC: DRVISION TECHNOLOGIES LLC Topic: 101Project Summary Neurological disorders significantly outnumber diseases in other therapeutic areas and are growing in incidence faster than any other disease classesHoweverthe pharmaceutical industry has been unsuccessful in coming up with effective drugsA big factor in these failures has been a lack of adequate model systems for fundamental disease understanding affecting both diagnosis and treat ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
CAMCI: Advancing the Use of Computerized Screening in Healthcare
SBC: Psychology Software Tools, Inc. Topic: NIACognitive dysfunction in the elderly population, ranging from simple forgetfulness to a diagnosis of Alzheimer’s disease, can impact one’s quality of life and ability to function in daily activities. It is crucial that decline be detected as early as possible in order to evaluate whether the cause is treatable, and to employ appropriate treatment, if applicable. The majority of older patients ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Kv7.2/7.3 Activators for the Treatment of Epilepsy Disorders
SBC: Knopp Biosciences LLC Topic: 106Project Summary Epilepsy is the oldest known and most common serious, chronic neurological disorder that is characterized by recurrent seizures. It currently affects 65 million people worldwide, including 2.3 million adults and nearly 470,000 children in the United States. People with epilepsy suffer from seizure-related disabilities, depression and anxiety and have increased mortality compared to ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP
SBC: PHARMAIN CORPORATION Topic: NHLBIABSTRACTThis application is seeking funding specifically for ChemistryManufacturingand ControlCMCof scale up production of long acting atrial natriuretic peptidedANPand its protected graft co polymerPGCexcipient for use in heart failureHFtreatmentThe extrinsic merit of this project will be the availability of cGMP grade PGC for use in prolonging the half life of various peptide drugs that are in p ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis
SBC: VIRTICI LLC Topic: NIAIDOur goal is to develop VTC MSas a novel tolerance inducing therapeutic to treat Multiple SclerosisMSMS is the most common demyelinating disorder of the Central Nervous SystemCNSaffecting approximatelymillion people worldwide andin the US aloneCurrent and developing treatment of MS relies mainly on immuno suppression and modulation to reduce inflammatory symptoms creating a significant need for new ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of an Open Speech Signal Processing Platform
SBC: SensorLogic, Inc. Topic: NIDCDThis proposal will create an open speech signal processing platform. The open computational framework will be used for developing algorithms that will help accelerate acoustic and hearing science research. It will permit researchers to more rapidly and easily test new algorithms with greater control, performance, and ease. Several example systems will be created to show that the platform can be ad ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
ExoSOUND:An Acoustofluidic Device for Exosome Isolation
SBC: Ascent Bio-Nano Technologies Inc Topic: 400Project Summary Exosomes are extracellular vesiclesnmfound in nearly all biological fluidsincluding bloodurinesalivaand cerebrospinal fluidIn recent years they have emerged as a potentially powerful tool for biomedical researchbiomarker discoverydisease diagnosticsand health monitoringExosomes perform diverse cellular functions such as intercellular communicationantigen presentationand transfer of ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Peptide Therapeutic for Obesity
SBC: VIRTICI LLC Topic: 300Project Summary The goal of this project is to develop a novel peptide therapeuticVTC Gfor the treatment of obesityTodayone third of adults in the United StatesUSare obesewith an estimated annual healthcare burden of approximately $billionByit is projected that overof adults in the US will be obese with a yearly healthcare burden expected to exceed $billionwhich will account for approximatelyof th ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health